Abstract
Deep-research article on berberine and blood-sugar markers in human randomized trials of type 2 diabetes. CDC National Diabetes Statistics Report estimates for 2023 put total diabetes (diagnosed or undiagnosed) at 40.1 million people, 12.0% of the U.S. population; CDC MMWR data from the 2016 National Health Interview Survey put crude diagnosed type 2 diabetes prevalence at 11.52% among non-Hispanic Black adults versus 7.99% among non-Hispanic White adults. A 2012 meta-analysis of 14 randomized trials (1,068 participants, all conducted in China; berberine ~0.9-1.5 g/day for 8-24 weeks) found berberine plus lifestyle improved glycemic markers more than lifestyle alone, berberine added to oral diabetes medicines improved control versus those medicines alone, and berberine was not significantly better than metformin, glipizide, or rosiglitazone in direct comparison. A 2008 Shanghai pilot trial (n=84; berberine 500 mg three times daily for 13 weeks) found A1c 9.5% to 7.5% (-2.0 percentage points), similar to metformin, with transient gastrointestinal effects in 34.5% of participants. Evidence grade: MODERATE (trial quality generally low per the meta-analysts). No Black or African American participants were included in this trial literature and no complications outcomes were measured. Educational article from the Buddha Ayurvedic School of Medicine: https://buddha.hospital